|
This special 2007 CME newsletter series is being developed to help
identify CKD anemia in diabetes and the elderly, focusing on managed and
long-term care, and the safety of erythropoietin therapy.
Erythropoietin Therapy:
Putting Safety in Perspective
December 2007
Learning Objectives
After reading this review, health care providers should be able to:
-
Describe the appropriate use of erythropoietin therapy in correcting anemia of
chronic kidney disease (CKD)
-
Review the safety profile of erythropoietin use when treating CKD-related anemia
-
Identify the safety concerns relating to erythropoietin use in chemotherapyinduced
anemia
-
Discuss the clinical application and dosing recommendations for epoetin
alfa and darbepoetin alfa in treating CKD-related anemia
Click here for full text
Anemia in the Elderly Patient:
Diagnosis and Treatment
September 2007
Learning Objectives
After reading this review, health care providers should be able to:
-
Discuss the disease burden and impact on quality of living related to anemia in
the elderly
-
Review the diagnosis, prevalence, and causes of anemia in the elderly
-
Discuss treatment options such as the extended dosing of erythropoietins for the
effective management of CKD-related anemia in the long-term care setting
-
Review the pharmacoeconomic and reimbursement issues relative to treating
anemia in the elderly
Click here for full text
Diabetes and anemia in the CKD patient
August 2007
Learning Objectives
After reading this issue, the reader should be able to:
-
Review the relationship between diabetes and chronic kidney
disease (CKD)
-
Describe the importance of glycemic control to minimize
microvascular and macrovascular complications in patients with diabetes and
CKD
-
Discuss the prevalence of anemia as a comorbidity in
patients with diabetes and CKD
-
Identify effective treatment of anemia in patients with
diabetes and CKD
-
Describe the use of extended dosing with erythropoiesis-stimulating
agents for treating CKD-related anemia
Click here for full text
Anemia in the Elderly Patient:
Diagnosis and Treatment
September 2007
Learning Objectives
After reading this review, health care providers should be able to:
-
Discuss the disease burden and impact on quality of living related to anemia in
the elderly
-
Review the diagnosis, prevalence, and causes of anemia in the elderly
-
Discuss treatment options such as the extended dosing of erythropoietins for the effective management of CKD-related anemia in the long-term care setting
-
Review the pharmacoeconomic and reimbursement issues relative to treating anemia in the elderly
Click here for full text
Diabetes and anemia in the CKD patient
August 2007
Learning Objectives
After reading this issue, the reader should be able to:
-
Review the relationship between diabetes and chronic kidney
disease (CKD)
-
Describe the importance of glycemic control to minimize
microvascular and macrovascular complications in patients with diabetes and
CKD
-
Discuss the prevalence of anemia as a comorbidity in
patients with diabetes and CKD
-
Identify effective treatment of anemia in patients with
diabetes and CKD
-
Describe the use of extended dosing with erythropoiesis-stimulating
agents for treating CKD-related anemia
Click here for full text
Managing Anemia in Chronic Kidney Disease
December 2006
Learning Objectives
After reading this issue, the reader should be able to:
-
Discuss effective methods to screen patients for CKD and anemia
-
List common comorbidities that contribute to morbidity and mortality of CKD
-
Review the importance of treating anemia in CKD
-
Describe the indications for oral and intravenous iron therapy
-
Discuss the indications and use of erythropoiesis-stimulating agent therapy in treating anemia
Click here for full text
CKD - A Rationale for Early Intervention
November 2006
Learning Objectives
After reading this issue, the reader should be able to:
-
Identify patients at risk for chronic kidney disease (CKD) and anemia
-
Discuss effective methods to screen patients for CKD and anemia
-
List common comorbidities that contribute to morbidity and mortality of CKD
-
Review the importance of aggressive treatment of comorbid disease.
Click here for full text
|
